Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Johann K. Hitzler, Todd A. Alonzo, Robert Gerbing, Jim Wang, Amy Beckman, Betsy Hirsch, Susana C. Raimondi, Karen M Chisholm, Shelton A. Viola, Anupam Verma, Lisa Eidenschink Brodersen, Michael R. Loken, Jeffrey W. Taub, Alan S Gamis, E. Anders Kolb, Todd M Cooper, Jason N. Berman

Blood (2024) 144 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2024-202621

Published: 2024

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

Richard J Marrero, Vivek M. Shastri, Richard Aplenc, Todd Cooper, Todd A. Alonzo, Alan S Gamis, Jim Wang, Soheil Meshinchi, E. Anders Kolb, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2023-187515

Published: 2023

Journal Articles

A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients

Francisco Marchi, Marieke Landwehr, Fernando Sckaff, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, Richard Aplenc, Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 835.

https://doi.org/10.1182/blood-2023-186505

Published: 2023

Journal Articles

Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

Nam Nguyen, Phani Krishna Parcha, Abderrahmane Tagmount, Bailey Gregory, Jeffrey E. Rubnitz, Raul C. Ribeiro, Xueyuan Cao, Todd A. Alonzo, Richard Aplenc, Alan S Gamis, Todd Cooper, E. Anders Kolb, Soheil Meshinchi, Stanley Pounds, Christopher Vulpe, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2023-178832

Published: 2023

Journal Articles

The Methylome Atlas of Acute Leukemia Enables Novel Clinical Diagnostic Tool for AML

Blood (2023) 142 (Supplement 1): 121.

https://doi.org/10.1182/blood-2023-186894

Published: 2023

Journal Articles

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Benjamin J Huang, Lauren K. Meyer, Adam Lamble, Jim Wang, Rhonda E Ries, Alan S Gamis, Richard Aplenc, Katherine Tarlock, Todd Cooper, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Joseph Chewning, William G. Woods, John T. Horan

Blood (2023) 142 (Supplement 1): 655.

https://doi.org/10.1182/blood-2023-186955

Published: 2023

Journal Articles

Europeanpediatric Acute Leukemia (EuPAL) Registry

Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh, Gwen Nichols, Laura Di Laurenzio, Michele S. Redell, Todd Cooper, E. Anders Kolb, Sarah K. Tasian, Franco Locatelli, C. Michel Zwaan, Dirk Reinhardt

Blood (2023) 142 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2023-189684

Published: 2023

Journal Articles

Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia

Satyavardhan Rao Nittu, Francisco Marchi, Nam Nguyen, Vivek M. Shastri, Xueyuan Cao, Raul C. Ribeiro, Jeffrey E. Rubnitz, Alan S Gamis, E. Anders Kolb, Richard Aplenc, Jeffery Klco, Stanley Pounds, Todd A. Alonzo, Soheil Meshinchi, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2926.

https://doi.org/10.1182/blood-2023-189029

Published: 2023

Journal Articles

Establishing Real-World Data-Driven Response Criteria in Pediatric Acute Myeloid Leukemia

Richard Aplenc, Yimei Li, Julianne Ani, Caitlin W. Elgarten, Lisa D'Errico, Todd Cooper, E. Anders Kolb, Maria Monica Gramatges, Meret Henry, Tamara P. Miller, Rajen Mody, Elaine Morgan, Regina M. Myers, Jessica A. Pollard, Alix Seif, Brian T. Fisher, Kelly D. Getz

Blood (2023) 142 (Supplement 1): 726.

https://doi.org/10.1182/blood-2023-185647

Published: 2023

Journal Articles

Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report

Lucie M. Turcotte, Jillian A. Whitton, Wendy M. Leisenring, Rebecca M. Howell, Joseph P. Neglia, Rachel Phelan, Kevin C. Oeffinger, Kirsten K. Ness, William G. Woods, E. Anders Kolb, Leslie L. Robison, Gregory T. Armstrong, Eric J. Chow

Blood (2023) 141 (1): 90–101.

https://doi.org/10.1182/blood.2022016487

Published: 2023

Includes: Supplemental data

Journal Articles

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Sae Ishimaru, Gwenaëlle Gueguen, Seth E. Karol, Francisco J. Bautista Sirvent, Valeria Ceolin, Bianca F. Goemans, Marlous Bakker, Laura Di Laurenzio, Jennifer Lukin, Harm Van Tinteren, Gauri B. Sunkersett, Maika Onishi, Kristina Unnebrink, Dirk Reinhardt, Gwen L Nichols, E. Anders Kolb, C. Michel Zwaan

Blood (2022) 140 (Supplement 1): 3369–3370.

https://doi.org/10.1182/blood-2022-168818

Published: 2022

Journal Articles

Azacitidine and Panobinostat Overcome Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A- rearranged Pediatric AML

Kara Lehner, Anilkumar Gopalakrishnapillai, E. Anders Kolb, Sonali P. Barwe

Blood (2022) 140 (Supplement 1): 5963–5964.

https://doi.org/10.1182/blood-2022-171114

Published: 2022

Journal Articles

Preclinical Validation of EZH2 and HDAC I Dual Inhibition As a Potent Therapy for Refractory Myeloid Leukemia Associated with Down Syndrome

Kader Cicek, Joshua R. Faust, Meredith Tavenner, E. Anders Kolb, Sonali P. Barwe, Anilkumar Gopalakrishnapillai

Blood (2022) 140 (Supplement 1): 5951–5952.

https://doi.org/10.1182/blood-2022-170549

Published: 2022

Journal Articles

Selinexor Prolongs Survival in Patient-Derived Xenograft Models of Down Syndrome Myeloid Leukemia

Sonali P. Barwe, Yana Pikman, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2022) 140 (Supplement 1): 8817–8818.

https://doi.org/10.1182/blood-2022-170441

Published: 2022

Journal Articles

A Bone Marrow Mimetic 3D Co-Culture Model for Ex Vivo drug Testing of Down Syndrome-Myeloid Leukemia Cells

Ishnoor Sidhu, Sonali P. Barwe, Kristi Lynn Kiick, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2022) 140 (Supplement 1): 8805–8806.

https://doi.org/10.1182/blood-2022-170637

Published: 2022

Journal Articles

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

Andrew J. Menssen, Chad A. Hudson, Todd A. Alonzo, Robert B. Gerbing, Laura Pardo, Fan-Chi Hsu, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, Yi-Cheng Wang, E. Anders Kolb, Todd M. Cooper, Jessica A. Pollard, Michael R. Loken, Richard Aplenc, Lisa Eidenschink Brodersen, Soheil Meshinchi

Blood (2022) 140 (Supplement 1): 3452–3453.

https://doi.org/10.1182/blood-2022-163682

Published: 2022

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

Hydrogel-Based 3D Culture Model for Down Syndrome Associated Transient Myeloproliferative Disorder Using Customized Induced Pluripotent Stem Cells

Ishnoor Sidhu, Sonali P. Barwe, Kristi Lynn Kiick, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2021) 138 (Supplement 1): 1137.

https://doi.org/10.1182/blood-2021-151274

Published: 2021

Journal Articles

Introduction of STAG2 Mutation in an iPSC Model of Transient Abnormal Myelopoiesis Mimics Down Syndrome Myeloid Leukemia

Ishnoor Sidhu, Sonali P. Barwe, E. Anders Kolb, Anilkumar Gopalakrishnapillai

Blood (2021) 138 (Supplement 1): 1138.

https://doi.org/10.1182/blood-2021-151875

Published: 2021

NARROW

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

A DNA Methylation Signature Predicts Clinical Outcome in Pediatric AML Patients

Leveraging Custom CRISPR/Cas9 Screens to Identify AraC-Daunorubicin-Etoposide (ADE), Gemtuzumab Ozogamicin (GO), and Bortezomib Response Modulators Association with Clinical Outcomes in Pediatric AML

The Methylome Atlas of Acute Leukemia Enables Novel Clinical Diagnostic Tool for AML

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Europeanpediatric Acute Leukemia (EuPAL) Registry

Relapse-Enriched Gene Expression Signature of Prognostic Relevance in Pediatric Acute Myeloid Leukemia

Establishing Real-World Data-Driven Response Criteria in Pediatric Acute Myeloid Leukemia

Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Azacitidine and Panobinostat Overcome Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A- rearranged Pediatric AML

Preclinical Validation of EZH2 and HDAC I Dual Inhibition As a Potent Therapy for Refractory Myeloid Leukemia Associated with Down Syndrome

Selinexor Prolongs Survival in Patient-Derived Xenograft Models of Down Syndrome Myeloid Leukemia

A Bone Marrow Mimetic 3D Co-Culture Model for Ex Vivo drug Testing of Down Syndrome-Myeloid Leukemia Cells

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Hydrogel-Based 3D Culture Model for Down Syndrome Associated Transient Myeloproliferative Disorder Using Customized Induced Pluripotent Stem Cells

Introduction of STAG2 Mutation in an iPSC Model of Transient Abnormal Myelopoiesis Mimics Down Syndrome Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only